S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Other Receivables
ÂĄ9.4m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Receivables
ÂĄ685.6m
CAGR 3-Years
55%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Receivables
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Receivables
ÂĄ92.2m
CAGR 3-Years
36%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Receivables
ÂĄ8m
CAGR 3-Years
-23%
CAGR 5-Years
-34%
CAGR 10-Years
-25%
Imeik Technology Development Co Ltd
SZSE:300896
Other Receivables
ÂĄ24.8m
CAGR 3-Years
17%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Receivables?
Other Receivables
9.4m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Other Receivables amounts to 9.4m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 3Y
13%

Over the last year, the Other Receivables growth was -47%. The average annual Other Receivables growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 13% over the past three years .

Back to Top